NewAmsterdam Pharma Full Year 2023 Earnings: Revenues Miss Expectations
NewAmsterdam Pharma (NASDAQ:NAMS) Full Year 2023 Results
Key Financial Results
Revenue: US$14.1m (down 87% from FY 2022).
Net loss: US$176.9m (loss widened by 112% from FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
NewAmsterdam Pharma Revenues Disappoint
Revenue missed analyst estimates by 8.6%.
Looking ahead, revenue is forecast to grow 57% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are up 6.0% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 3 warning signs for NewAmsterdam Pharma that you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
